Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The cooperation between hMena overexpression and HER2 signalling in breast cancer.
Di Modugno F, Mottolese M, DeMonte L, Trono P, Balsamo M, Conidi A, Melucci E, Terrenato I, Belleudi F, Torrisi MR, Alessio M, Santoni A, Nisticò P. Di Modugno F, et al. Among authors: mottolese m. PLoS One. 2010 Dec 30;5(12):e15852. doi: 10.1371/journal.pone.0015852. PLoS One. 2010. PMID: 21209853 Free PMC article.
The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
Di Modugno F, Mottolese M, Di Benedetto A, Conidi A, Novelli F, Perracchio L, Venturo I, Botti C, Jager E, Santoni A, Natali PG, Nisticò P. Di Modugno F, et al. Among authors: mottolese m. Clin Cancer Res. 2006 Mar 1;12(5):1470-8. doi: 10.1158/1078-0432.CCR-05-2027. Clin Cancer Res. 2006. PMID: 16533770 Free article.
Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.
Pino MS, Balsamo M, Di Modugno F, Mottolese M, Alessio M, Melucci E, Milella M, McConkey DJ, Philippar U, Gertler FB, Natali PG, Nisticò P. Pino MS, et al. Among authors: mottolese m. Clin Cancer Res. 2008 Aug 1;14(15):4943-50. doi: 10.1158/1078-0432.CCR-08-0436. Clin Cancer Res. 2008. PMID: 18676769 Free PMC article.
Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.
Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L, Carstens RP, Santoni A, Bissell MJ, Nisticò P. Di Modugno F, et al. Among authors: mottolese m. Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19280-5. doi: 10.1073/pnas.1214394109. Epub 2012 Nov 5. Proc Natl Acad Sci U S A. 2012. PMID: 23129656 Free PMC article.
hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis.
Di Modugno F, Spada S, Palermo B, Visca P, Iapicca P, Di Carlo A, Antoniani B, Sperduti I, Di Benedetto A, Terrenato I, Mottolese M, Gandolfi F, Facciolo F, Chen EI, Schwartz MA, Santoni A, Bissell MJ, Nisticò P. Di Modugno F, et al. Among authors: mottolese m. Oncogene. 2018 Oct;37(42):5605-5617. doi: 10.1038/s41388-018-0364-3. Epub 2018 Jun 15. Oncogene. 2018. PMID: 29907768 Free PMC article.
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.
Folgiero V, Avetrani P, Bon G, Di Carlo SE, Fabi A, Nisticò C, Vici P, Melucci E, Buglioni S, Perracchio L, Sperduti I, Rosanò L, Sacchi A, Mottolese M, Falcioni R. Folgiero V, et al. Among authors: mottolese m. PLoS One. 2008 Feb 13;3(2):e1592. doi: 10.1371/journal.pone.0001592. PLoS One. 2008. PMID: 18270579 Free PMC article.
p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.
Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, Pizzuti L, Sergi D, Terrenato I, Esposito L, Iannuzzi CA, Pasquale R, Botti C, Fuhrman B, Giordano A, Mottolese M, Barba M. Vici P, et al. Among authors: mottolese m. Oncotarget. 2014 Nov 15;5(21):10382-92. doi: 10.18632/oncotarget.2060. Oncotarget. 2014. PMID: 25071015 Free PMC article.
243 results